Literature DB >> 30830568

Prognostic Significance of IL-6 in Hodgkin Lymphoma.

Sainath Bhethanabhotla1,2, Akash Tiwari1,2, M C Sharma3, Sreenivas Vishnubhatla4, Sameer Bakhshi5,6.   

Abstract

Elevated serum interleukin-6 (IL-6) in Hodgkin lymphoma (HL) is reported to correlate with B symptoms, response rate and survival in adult patients. The authors studied prognostic significance of IL-6 expression by immunohistochemistry on Hodgkin-Reed Sternberg cells and background reactive cells in a retrospective cohort of pediatric HL patients treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) from January 2009 through December 2013. Of 142 patients, tissue blocks were retrieved in 110 patients. On logistic regression analysis, IL-6 expression on background cells alone was among the factors associated with inferior response rate (OR-9.9, 95%CI-1.2, 78.3; p = 0.03). On multivariate analysis, IL-6 expression on background cells alone had significant impact on 5 y freedom from treatment failure (FFTF) (HR-7.7, 95% CI-1.2, 48.6; p = 0.03). IL-6 expression by immunohistochemistry in the background cells is an independent poor predictor of response and FFTF in pediatric HL. Further prospective studies in children are needed to confirm the current findings and whether IL-6 expression can be used to stratify treatment.

Entities:  

Keywords:  Interleukin-6; Pediatric Hodgkin lymphoma

Mesh:

Substances:

Year:  2019        PMID: 30830568     DOI: 10.1007/s12098-019-02902-x

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  11 in total

1.  Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease.

Authors:  C L Olweny
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

2.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

3.  Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.

Authors:  J F Seymour; M Talpaz; F B Hagemeister; F Cabanillas; R Kurzrock
Journal:  Am J Med       Date:  1997-01       Impact factor: 4.965

4.  Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  René-Olivier Casasnovas; Nicolas Mounier; Pauline Brice; Marine Divine; Franck Morschhauser; Jean Gabarre; Jean-Yves Blay; Laurent Voillat; Pierre Lederlin; Aspasia Stamatoullas; Jacques Bienvenu; Michel Guiguet; Liliane Intrator; Monique Grandjean; Josette Brière; Christophe Ferme; Gilles Salles
Journal:  J Clin Oncol       Date:  2007-03-26       Impact factor: 44.544

5.  Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.

Authors:  Sainath Bhethanabhotla; Sandeep Jain; Gauri Kapoor; Amita Mahajan; Anita Chopra; Sreenivas Vishnubhatla; Sameer Bakhshi
Journal:  Leuk Lymphoma       Date:  2016-12-06

6.  Serum cytokine levels correlate with clinical parameters in Hodgkin's disease.

Authors:  M Gorschlüter; H Bohlen; D Hasenclever; V Diehl; H Tesch
Journal:  Ann Oncol       Date:  1995-05       Impact factor: 32.976

7.  IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma.

Authors:  Wendy Cozen; Parkash S Gill; Sue Ann Ingles; Rizwan Masood; Otoniel Martínez-Maza; Myles G Cockburn; W James Gauderman; Malcolm C Pike; Leslie Bernstein; Bharat N Nathwani; Muhammad T Salam; Kathleen Lackerdas Danley; Wei Wang; Julia Gage; Susan Gundell-Miller; Thomas M Mack
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

8.  Serum concentrations of cytokines in patients with Hodgkin's disease.

Authors:  J Y Blay; J P Farcet; A Lavaud; D Radoux; S Chouaïb
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

Review 9.  Pediatric Hodgkin Lymphoma.

Authors:  Christine Mauz-Körholz; Monika L Metzger; Kara M Kelly; Cindy L Schwartz; Mauricio E Castellanos; Karin Dieckmann; Regine Kluge; Dieter Körholz
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

10.  Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.

Authors:  Preethi Reddy Marri; Lucy S Hodge; Matthew J Maurer; Steven C Ziesmer; Susan L Slager; Thomas M Habermann; Brian K Link; James R Cerhan; Anne J Novak; Stephen M Ansell
Journal:  Clin Cancer Res       Date:  2013-10-18       Impact factor: 12.531

View more
  2 in total

1.  Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.

Authors:  Alex Reza Gholiha; Peter Hollander; Ingrid Glimelius; Gustaf Hedstrom; Daniel Molin; Henrik Hjalgrim; Karin E Smedby; Jamileh Hashemi; Rose-Marie Amini; Gunilla Enblad
Journal:  Blood Adv       Date:  2021-03-23

2.  An Autopsy Case of an Elderly Patient with Classic Hodgkin Lymphoma Presenting with a Plethora of Clinical Symptoms and Signs.

Authors:  Hiroshi Kobayashi; Ryouya Seki; Masuo Ujita; Kana Hirayama; Satoshi Yamada; Riuko Ohashi; Yoshiro Otsuki; Takuya Watanabe; Tadashi Yoshino
Journal:  Am J Case Rep       Date:  2020-10-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.